Lomitapide treatment in a female with homozygous familial hypercholesterolaemia: a case report.

Karin LittmannKarolina SzummerHannes Hagström Karoly Dolapcsiev Jonas BrinckMats Eriksson

Published in: European heart journal. Case reports (2020)

In this female with homozygous FH adding lomitapide treatment to LDL apheresis has contributed to improved LDL-C levels, a reduction in LDL apheresis sessions and enhanced quality of life. No adverse effects have been reported. These findings suggest that lomitapide can be a drug of choice in patients with homozygous FH.

Keyphrases

early onset
combination therapy
decision making
smoking cessation
adverse drug